verified SJR 0,835 · Q2 • database Scopus / SJR & Web of Science indexed

United Kingdom · Taylor and Francis Ltd.

workspace_premium Q2 — Immunology lock Subscription

Immunotherapy

Immunotherapy is a journal indexed in SJR in Immunology and Immunology and Allergy with an H index of 69. It has an SJR impact factor of 0,835 and it has a best quartile of Q2. It has an SJR impact factor of 0,835.

Immunotherapy focuses its scope in these topics and keywords: immunotherapy, cell, model, immune, t, cells, adoptive, inhibitors, micethe, pathway, ...

ISSN: 1750-743X

Publisher: Taylor and Francis Ltd.

Category: Immunology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,835 Q2

H-index 69

Acceptance rate pie_chart

30% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,835

H-index

Docs (year)

124

Docs 3y

427

Total refs

5082

Cites 3y

1048

Citable 3y

406

Cites/Doc 2y

2.26

Ref/Doc

40.98

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy

Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies

Conference Scene: 15th International Conference on Human Antibodies and Hybridomas: summary and update

Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis

Chronic inflammation and immunologic-based constraints in malignant disease

Chemokine-based immunotherapy: delivery systems and combination therapies

Cellular immunotherapy with ex vivo expanded cord blood T cells in a humanized mouse model of EBV-associated lymphoproliferative disease

Carboplatin hypersensitivity: evaluation and successful desensitization protocol

Cancer CARtography: charting out a new approach to cancer immunotherapy

Biologics in spondyloarthritis: TNFa inhibitors and other agents

Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI)

Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease

SHOW MORE ARTICLES

Are chemokines therapeutic targets for the prevention of preterm labor?

gammad T cell-based anticancer immunotherapy: progress and possibilities

Antithymocyte globulin-induced hemolytic anemia and thrombocytopenia after kidney transplantation

Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis

Anti-abeta-T-cell receptor antibodies in the setting of laryngeal transplantation

An update on current and prospective immunotherapies for chronic lymphocytic leukemia

Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations

Allergen immunotherapy, routes of administration and cytokine networks: an update

Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation

Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB

A review of ustekinumab in the treatment of psoriatic arthritis

A Phase I clinical trial with subcutaneous immunotherapy vaccine of Timothy grass pollen extract according to EMA guidelines

FAQs

Immunotherapy has an SJR of 0,835 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Immunotherapy is 30%.

Immunotherapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Immunotherapy?

What is the APC / publication cost?

What is the acceptance rate?